UI Hospitals and Clinics
A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib
The purpose of this study is to test the effectiveness of the research study drugs LY2875358 and erlotinib in making tumors smaller in patients with metastatic non-small cell lung cancer. This is a research study to test the effectiveness of LY2875358 and erlotinib, also known as "investigational." This means the drug has not been approved by the U.S. Food and Drug Administration (FDA) for the use described in this study. However, the FDA has allowed the use of this drug for research. About 100 people will be enrolled in the study.
Susan Gillen 319-467-5827
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.